Market Cap 1.51B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 5,951,000
Avg Vol 5,141,984
Day's Range N/A - N/A
Shares Out 305.27M
Stochastic %K 46%
Beta 1.02
Analysts Strong Sell
Price Target $9.43

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
tradersunion353
tradersunion353 May. 14 at 1:52 PM
$ABCL 3rd day in row ABCL pos dropped 20% since releasing phase 1 data yes this is extremely bullish as per married to ABCL folks here by the way .. DEMEM guy must be coming up new theorie
0 · Reply
DeMampCamp
DeMampCamp May. 14 at 1:46 PM
0 · Reply
tradersunion353
tradersunion353 May. 14 at 12:59 PM
$ABCL overhyped with so many fake longs and accounts here until the share price syncs up hype ABCL is overhyped underperforming junk
0 · Reply
tranq19
tranq19 May. 14 at 10:01 AM
$ABCL my takeaways from the Bank of America call. For the phase 2 read out on 635, according to Carl it’s just whether it’s one bottle of champagne or two if the efficacy is a home run. For 688 and 386 seems just as excited and once 635 comes through if it does, just those announcements will be in big news 
1 · Reply
snowPOW
snowPOW May. 14 at 2:50 AM
$ABCL over 21% short interest https://fintel.io/ss/us/abcl On an underlying asset that keeps improving? Sure
1 · Reply
Stocktradesmoon
Stocktradesmoon May. 14 at 1:01 AM
$ABCL $ABCL Short and sweet from Carl today. TL;DR “we have best in world capabilities integrated into our platform and its differentiated. We’ll be developing drugs with high technical barriers and low competition. The market doesn’t care about a story and wants to see results. Fair enough - we’ll show you with results” I’m paraphrasing here, but that was the main takeaway I had. For 635, management is not promising or saying they “expect” this, but did once again make note of the ~potential~ for improved efficacy. That would be huge. The bar right now is set for equivalent efficacy to small molecules with improved safety and dosing (monthly). Let’s see if they can hit the trifecta and get improved efficacy as well.
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 14 at 12:26 AM
$ABCL Part 1 $ABCL Just now @ BoA - @AbCelleraBio CEO Carl Hansen when asked about what the market is overlooking: “I believe we now have best in class or best in world capabilities for some very important specific applications in therapeutic antibodies. So GPCRs and ion channels has been a heavy focus. Our first program, which I am sure we are going to talk about, ABCL635, is emblematic of that capability. We also have developed capabilities in Multispecific and more recently in ADCs. So the platform build is highly differentiated. We can make molecules that are not ‘me too’, but are getting to some new space where there is not much competition. It is integrated all the way from discovery through now to manutacturing. That is a very unusual setup for a company.
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 14 at 12:25 AM
$ABCL Part 2 The market I think rightly does not want you to talk about a platform. They want to see what is the outcome of the platform. So for the last two years we have been setting that up. 635 is the first example. Next year we expect another two programs of a similar profile ABCL688 and ABCL386 to come forward. I believe over time we are going to be judged on the differentiation of the platform as seen in the assets as well as perception that we are taking that capital and that capability and directing it to bets that are going to have high return on investment.”
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 14 at 12:09 AM
$ABCL $ABCL AbCellera CEO Carl Hansen is now live at BoA Global Healthcare Conference
0 · Reply
tradersunion353
tradersunion353 May. 13 at 11:34 PM
$ABCL fake pumpers all over
0 · Reply
Latest News on ABCL
AbCellera price target raised to $8 from $7 at Stifel

2026-05-12T10:58:11.000Z - 2 days ago

AbCellera price target raised to $8 from $7 at Stifel


AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 days ago

AbCellera Biologics Earnings Call Transcript: Q1 2026


AbCellera initiated with an Overweight at Cantor Fitzgerald

2026-05-05T10:36:31.000Z - 9 days ago

AbCellera initiated with an Overweight at Cantor Fitzgerald


AbCellera initiated with a Buy at JonesResearch

2026-04-09T20:10:26.000Z - 4 weeks ago

AbCellera initiated with a Buy at JonesResearch


AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 2 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025


AbCellera reports FY25 EPS (49c) vs. (55c) last year

2026-02-24T21:15:21.000Z - 2 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year


AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 2 months ago

AbCellera Reports Full Year 2025 Business Results


AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 6 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors


AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025


AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 6 months ago

AbCellera Reports Q3 2025 Business Results


AbCellera appoints Sarah Noonberg as Chief Medical Officer

2025-09-10T13:20:54.000Z - 8 months ago

AbCellera appoints Sarah Noonberg as Chief Medical Officer

MGX


AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 8 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer


AbCellera doses first participants in Phase 1 trial of ABCL575

2025-08-27T13:20:26.000Z - 9 months ago

AbCellera doses first participants in Phase 1 trial of ABCL575


AbCellera price target raised to $7 from $5 at BMO Capital

2025-08-08T13:26:29.000Z - 9 months ago

AbCellera price target raised to $7 from $5 at BMO Capital


AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 9 months ago

AbCellera Biologics Earnings Call Transcript: Q2 2025


AbCellera assumed with an Outperform at Leerink

2025-07-07T10:40:33.000Z - 11 months ago

AbCellera assumed with an Outperform at Leerink


AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025


AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results


AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024


AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024


AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2024


AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024


AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results


tradersunion353
tradersunion353 May. 14 at 1:52 PM
$ABCL 3rd day in row ABCL pos dropped 20% since releasing phase 1 data yes this is extremely bullish as per married to ABCL folks here by the way .. DEMEM guy must be coming up new theorie
0 · Reply
DeMampCamp
DeMampCamp May. 14 at 1:46 PM
0 · Reply
tradersunion353
tradersunion353 May. 14 at 12:59 PM
$ABCL overhyped with so many fake longs and accounts here until the share price syncs up hype ABCL is overhyped underperforming junk
0 · Reply
tranq19
tranq19 May. 14 at 10:01 AM
$ABCL my takeaways from the Bank of America call. For the phase 2 read out on 635, according to Carl it’s just whether it’s one bottle of champagne or two if the efficacy is a home run. For 688 and 386 seems just as excited and once 635 comes through if it does, just those announcements will be in big news 
1 · Reply
snowPOW
snowPOW May. 14 at 2:50 AM
$ABCL over 21% short interest https://fintel.io/ss/us/abcl On an underlying asset that keeps improving? Sure
1 · Reply
Stocktradesmoon
Stocktradesmoon May. 14 at 1:01 AM
$ABCL $ABCL Short and sweet from Carl today. TL;DR “we have best in world capabilities integrated into our platform and its differentiated. We’ll be developing drugs with high technical barriers and low competition. The market doesn’t care about a story and wants to see results. Fair enough - we’ll show you with results” I’m paraphrasing here, but that was the main takeaway I had. For 635, management is not promising or saying they “expect” this, but did once again make note of the ~potential~ for improved efficacy. That would be huge. The bar right now is set for equivalent efficacy to small molecules with improved safety and dosing (monthly). Let’s see if they can hit the trifecta and get improved efficacy as well.
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 14 at 12:26 AM
$ABCL Part 1 $ABCL Just now @ BoA - @AbCelleraBio CEO Carl Hansen when asked about what the market is overlooking: “I believe we now have best in class or best in world capabilities for some very important specific applications in therapeutic antibodies. So GPCRs and ion channels has been a heavy focus. Our first program, which I am sure we are going to talk about, ABCL635, is emblematic of that capability. We also have developed capabilities in Multispecific and more recently in ADCs. So the platform build is highly differentiated. We can make molecules that are not ‘me too’, but are getting to some new space where there is not much competition. It is integrated all the way from discovery through now to manutacturing. That is a very unusual setup for a company.
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 14 at 12:25 AM
$ABCL Part 2 The market I think rightly does not want you to talk about a platform. They want to see what is the outcome of the platform. So for the last two years we have been setting that up. 635 is the first example. Next year we expect another two programs of a similar profile ABCL688 and ABCL386 to come forward. I believe over time we are going to be judged on the differentiation of the platform as seen in the assets as well as perception that we are taking that capital and that capability and directing it to bets that are going to have high return on investment.”
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 14 at 12:09 AM
$ABCL $ABCL AbCellera CEO Carl Hansen is now live at BoA Global Healthcare Conference
0 · Reply
tradersunion353
tradersunion353 May. 13 at 11:34 PM
$ABCL fake pumpers all over
0 · Reply
tradersunion353
tradersunion353 May. 13 at 11:03 PM
$ABCL overhyped junk most of them are paid by company to pump this POS
0 · Reply
8008track
8008track May. 13 at 11:03 PM
$ABCL t minus 1 hour
0 · Reply
Kaykay610
Kaykay610 May. 13 at 11:02 PM
$ABCL interestingly the only slightly questionable thing in the data is the pk data test they used to validate the engagement of the drug using males. In contrast to all that the phase three readout shows that the efficacy doesn't depend on testosterone levels so we will see
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 13 at 10:49 PM
0 · Reply
PhotonicDigger
PhotonicDigger May. 13 at 10:21 PM
$ABCL — what’s your take on this move? After earnings, expectations improved and price targets were raised, yet the stock kept drifting lower — a clear disconnect between fundamentals and price action. Some see this as an overreaction and potential opportunity, while others view it as the market pricing in hidden risks. So the question is: is this a mispricing opportunity, or the start of a weaker trend? Which side are you on? Free sharing and subscription 👉@PhotonicDigger.
3 · Reply
Samb2344
Samb2344 May. 13 at 9:28 PM
$ABCL bought more today just pump it 💯🙏🏻🚀
0 · Reply
Gemology
Gemology May. 13 at 8:38 PM
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 13 at 8:15 PM
$ABCL Make sure to tune into the call 5pm Pacific Bank of America. Link below ⬇️
0 · Reply
DeMampCamp
DeMampCamp May. 13 at 7:25 PM
$ABCL Wow, we went from an exciting couple weeks to a snooze fest today, let's shake out the last remaining short timers and get back to $5+!
1 · Reply
Samb2344
Samb2344 May. 13 at 6:43 PM
$ABCL who’s buying?
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 13 at 6:10 PM
$ABCL $ABCL "If you listen to others, not just on public markets but in your life, you will be blown off course. Having conviction and staying the course, I think, is probably the big thing." - Carl Hansen
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 13 at 5:40 PM
$ABCL $ABCL AbCellera collected the first $18 million of their $36 million litigation settlement with Bruker in Q1 2026, with the remaining $18.0 million expected in Q2. (Source: 10Q)
0 · Reply